FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps

Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent

Zota Health Care receives licnese for Zotamet and Telmisartan in Kyrgyzstan

Tezspire approved in the EU for the treatment of severe asthma

First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations

ZS and Quartic to accelerate digitalization in life sciences and healthcare

ZS and Quartic will collaborate to help drive resilience, increase adoption of Industry 4.0 and improve predictive decision-making across manufacturing

New data reinforces efficacy of Tezspire

These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Pharma tops India’s exports from SEZs

As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational

Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment

Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion

Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025

Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025

Shilpa Medicare's Unit IV receives Eurasia GMP approval

Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia